Last updated on January 2020

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis


Brief description of study

To evaluate the long-term safety of Spesolimab in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of Spesolimab in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials

Clinical Study Identifier: NCT03648541

Find a site near you

Start Over

Tokyo Yamate Medical Center

Tokyo, Shinjuku, Japan
3.41miles
  Connect »

Tokyo Medical and Dental University

Tokyo, Bunkyo-ku, Japan
6.8miles
  Connect »